Akeso Inc.

Akeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke

Results from a Phase III study in China of Akeso and Summit Therapeutics’ ivonescimab in non-small cell lung cancer (NSCLC) are an encouraging sign for the PD-1/VEGF-targeting bispecific antibody’s pi

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

Jiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US